Top Markets
Coin of the day
Hepion Pharmaceuticals, Inc. Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc.

HEPA
Classificação em ações #39072
Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is... Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease. It is currently progressing through clinical development for non-alcoholic steatohepatitis (NASH) and is additionally being explored in nonclinical research for its potential to reduce liver fibrosis and lessen hepatocellular carcinoma tumor loads in experimental models of NASH. Moreover, Rencofilstat has exhibited antiviral properties against hepatitis B, C, and D viruses through diverse mechanisms. The company, established in 2013 and situated in Edison, New Jersey, rebranded as Hepion Pharmaceuticals, Inc. in July 2019, having previously operated as ContraVir Pharmaceuticals, Inc.
Preço da ação
$0.0568
Última sincronização: 2026-08-13
Valor de mercado
$661.36K
Variação (1 dia)
11.37%
Variação (1 ano)
-5.33%
País
US
Negociar Hepion Pharmaceuticals, Inc. (HEPA)

Categoria

Histórico de preços das ações de Hepion Pharmaceuticals, Inc. (HEPA)
Preço de fecho mais alto: $0.05 em 2026-08-01

Preço de fecho mais baixo: $815.99K em 2014-02-01
Histórico de preços das ações da Hepion Pharmaceuticals, Inc. de 2014 a 2026
Desempenho anual do preço das ações
Ano Desempenho
2026 (TTM) -13.53%
2025 -99.75%
2024 -83.90%
2023 -47.81%
2022 -72.98%
2021 -35.82%
2020 -64.66%
2019 -80.01%
2018 -87.43%
2017 -77.91%
2016 -3.97%
2015 1.80%
2014 0.00%
Preço das ações de empresas similares ou concorrentes
Empresa Preço da ação Variação 1a% País
$517.18 32.51%
US
$857.76 31.47%
NL
$728.05 6.60%
CH
$1.07K -6.40%
KR
$254.79 12.56%
BE